Saxena Nishant C 4

What Happened

• Nishant C. Saxena, Chief Business Officer of Corbus Pharmaceuticals (CRBP), received equity awards on May 21, 2026: 58,300 restricted stock units (RSUs) and a 192,300-share derivative award (total 250,600 units). Both awards were granted at a $0.00 purchase price (typical for compensation grants) and are unvested at grant.

Key Details

• Transaction date: May 21, 2026 (Form 4 filed May 22, 2026 — timely filing).
• Awards: 58,300 RSUs (settled in common stock) + 192,300 derivative award (reported as a derivative grant).
• Price: $0.00 per share (grant price = $0 at issuance); total intrinsic cash paid = $0.
• Vesting (RSUs): 25% vest on each of the first four anniversaries beginning May 21, 2027. RSUs include a partial acceleration provision if the Company terminates Saxena without cause after the first vesting date (prorated acceleration toward next vesting); unvested RSUs are otherwise forfeited on termination.
• Vesting (derivative/option): Annual option award per the 2024 Equity Compensation Plan. 25% vests May 21, 2027; remaining 75% vests in equal monthly installments over 36 months beginning June 21, 2027.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Reported on May 22, 2026 for a May 21, 2026 grant — appears timely. No 10b5-1 plan, tax withholding, or sale noted in this filing.

Context

• These are compensation grants (code A) and not open-market purchases or sales; such awards are part of executive compensation and do not necessarily indicate a change in personal market view.
• The 192,300 derivative award reflects an option/other equity right with a multi-year vesting schedule — the shares are not immediately tradable until vested and, if options, typically require exercise.